Antisense hippocampal knockdown of NMDA-NR1 by HVJ-liposome vector induces deficit of prepulse inhibition but not of spatial memory

Neuroscience Research

Volumn 45, Issue 4, 2003, Pages 473-481

  Inada, Ken ^a   Ishigooka, Jun ^a   Anzai, Takeshi ^a   Suzuki, Eiji ^a   Miyaoka, Hitoshi ^a   Saji, Makoto ^b  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Antisense; Hippocampus; NMDA; Prepulse inhibition; Rat; Water maze

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BRAIN PROTEIN; LIPOSOME; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RECEPTOR SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; DOWN REGULATION; GENE TRANSFER; HIPPOCAMPUS; MALE; MAZE TEST; NONHUMAN; PARAINFLUENZA VIRUS 1; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSORIMOTOR FUNCTION; SPATIAL MEMORY; TASK PERFORMANCE; WESTERN BLOTTING;

EID: 0037379074     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-0102(03)00012-9     Document Type: Article

References (34)

1. Bakshi V.P., Geyer M.A. Multiple limbic regions mediate the disruption of prepulse inhibition produced in rats by the noncompetitive NMDA antagonist dizocilpine. J. Neurosci. 18:(20):1998;8394-8401.
2. Braff D.L., Geyer M.A. Sensorimotor gating and schizophrenia. Human and animal model studies. Arch. Gen. Psychiatry. 47:(2):1990;181-188.
3. Braff D.L., Grillon C., Geyer M.A. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry. 49:(3):1992;206-215.
4. Braff D.L., Geyer M.A., Light G.A., Sprock J., Perry W., Cadenhead K.S., Swerdlow N.R. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr. Res. 49:2001;171-178.
5. Corbett R., Camacho F., Woods A.T., Kerman L.L., Fishkin R.J., Brooks K., Dunn R.W. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berlin). 120:(1):1995;67-74.
6. Duncan G.E., Sheitman B.B., Lieberman J.A. An integrated view of pathophysiological models of schizophrenia. Brain Res. Brain Res. Rev. 29:(2-3):1999;250-264.
7. Duncan G.E., Zorn S., Lieberman J.A. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol. Psychiatry. 4:1999;418-428.
8. Forrest D., Yuzaki M., Soares H.D., Ng L., Luk D.C., Sheng M., Stewart C.L., Morgan J.I., Connor J.A., Curran T. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron. 13:(2):1994;325-338.
9. Gainetdinov R.R., Mohn A.R., Caron M.G. Genetic animal models: focus on schizophrenia. Trends Neurosci. 24:2001;527-533.
10. Geyer M.A. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry. 31:(Suppl. 2):1998;73-79.
11. Goldberg T.E., Weinberger D.R., Pliskin N.H., Berman K.F., Podd M.H. Recall memory deficit in schizophrenia. A possible manifestation of prefrontal dysfunction. Schizophr. Res. 2:(3):1989;251-257.
12. Kaneda Y. Development of a novel fusogenic viral liposome system (HVJ-liposomes) and its applications to the treatment of acquired diseases. Mol. Membr. Biol. 16:1999;119-122.
13. Kaneda Y., Uchida T., Kim J., Ishiura M., Okada Y. The improved efficient method for introducing macromolecules into cells using HVJ (Sendai virus) liposomes with gangliosides. Exp. Cell. Res. 173:(1):1987;56-69.
14. Kutsuwada T., Kashiwabuchi N., Mori H., Sakimura K., Kushiya E., Araki K., Meguro H., Masaki H., Kumanishi T., Arakawa M., et al. Molecular diversity of the NMDA receptor channel. Nature. 358:1992;36-41.
15. Matthies H., Schroder H., Wagner M., Hollt V., Krug M. NMDA/R1-antisense oligonucleotide influences the early stage of long-term potentiation in the CA1-region of rat hippocampus. Neurosci. Lett. 202:(1-2):1995;113-116.
16. Mohn A.R., Gainetdinov R.R., Caron M.G., Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 98:(4):1999;427-436.
17. Monyer H., Sprengel R., Schoepfer R., Herb A., Higuchi M., Lomeli H., Burnashev N., Sakmann B., Seeburg P.H. Heteromeric NMDA receptors: molecular and functional distinction of subtypes. Science. 256:1992;1217-1221.
18. Morris R.G., Garrud P., Rawlins J.N., O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature. 297:(5868):1982;681-683.
19. Morris R.G., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-776.
20. Noda Y., Kamei H., Mamiya T., Furukawa H., Nabeshima T. Repeated phencyclidine treatment induces negative symptom-like behavior in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology. 23:2000;375-387.
21. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:(12):1995;998-1007.
22. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33:(6):1999;523-533.
23. Roberts E.B., Meredith M.A., Ramoa A.S. Suppression of NMDA receptor function using antisense DNA block ocular dominance plasticity while preserving visual responses. J. Neurophysiol. 80:(3):1998;1021-1032.
24. Saeki Y., Matsumoto N., Nakano Y., Mori M., Awai K., Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum. Gene Ther. 8:(17):1997;2133-2141.
25. Sams Dodd F. Effects of continuous D-amphetamine and phencyclidine administration on social behavior, stereotyped behavior, and locomotor activity in rats. Neuropsychopharmacology. 19:1998;18-25.
26. Schmand B., Kop W.J., Kuipers T., Bosveld J. Implicit learning in psychotic patients. Schizophr. Res. 7:(1):1992;55-64.
27. Standaert D.G., Testa C.M., Rudolf G.D., Hollingsworth Z.R. Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation. J. Pharmacol. Exp. Ther. 276:(1):1996;342-352.
28. Swerdlow N.R., Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr. Bull. 24:1998;285-301.
29. Tamlyn D., McKenna P.J., Mortimer A.M., Lund C.E., Hammond S., Baddeley A.D. Memory impairment in schizophrenia: its extent, affiliations and neuropsychological character. Psychol. Med. 22:(1):1992;101-115.
30. Toru M., Kurumaji A., Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci. 55:(22):1994;1683-1699.
31. Tsien J.Z., Huerta P.T., Tonegawa S. The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 87:(7):1996;1327-1338.
32. Wahlestedt C., Golanov E., Yamamoto S., Yee F., Ericson H., Yoo H., Inturrisi C.E., Reis D.J. Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature. 363:(6426):1993;260-263.
33. Yamada K., Moriguchi A., Morishita R., Aoki M., Nakamura Y., Mikami H., Oshima T., Ninomiya M., Kaneda Y., Higaki J., Ogihara T. Efficient oligonucleotide delivery using the HVJ-liposome method in the central nervous system. Am. J. Physiol. 271:(5 Pt 2):1996;R1212-R1220.
34. Zapata A., Capdevila J.L., Tarrason G., Adan J., Martinez J.M., Piulats J., Trullas R. Effects of NMDA-R1 antisense oligodeoxynucleotide administration: behavioral and radioligand binding studies. Brain Res. 745:(1-2):1997;114-120.